IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v494y2013i7436d10.1038_nature11814.html
   My bibliography  Save this article

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

Author

Listed:
  • Meghna Das Thakur

    (Novartis Institutes for Biomedical Research)

  • Fernando Salangsang

    (Novartis Institutes for Biomedical Research)

  • Allison S. Landman

    (University of California San Francisco)

  • William R. Sellers

    (Novartis Institutes for Biomedical Research)

  • Nancy K. Pryer

    (Novartis Institutes for Biomedical Research)

  • Mitchell P. Levesque

    (University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland)

  • Reinhard Dummer

    (University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland)

  • Martin McMahon

    (University of California San Francisco)

  • Darrin D. Stuart

    (Novartis Institutes for Biomedical Research)

Abstract

BRAF inhibitors such as vemurafenib have shown promising effects in patients with BRAF-mutant melanomas, but the tumours generally develop resistance; vemurafenib-resistant melanomas are now shown to be drug dependent, and an intermittent dosing schedule can help prevent drug resistance.

Suggested Citation

  • Meghna Das Thakur & Fernando Salangsang & Allison S. Landman & William R. Sellers & Nancy K. Pryer & Mitchell P. Levesque & Reinhard Dummer & Martin McMahon & Darrin D. Stuart, 2013. "Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance," Nature, Nature, vol. 494(7436), pages 251-255, February.
    • Handle: RePEc:nat:nature:v:494:y:2013:i:7436:d:10.1038_nature11814
    DOI: 10.1038/nature11814
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature11814
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature11814?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Guillaume Harmange & Raúl A. Reyes Hueros & Dylan L. Schaff & Benjamin Emert & Michael Saint-Antoine & Laura C. Kim & Zijian Niu & Shivani Nellore & Mitchell E. Fane & Gretchen M. Alicea & Ashani T. W, 2023. "Disrupting cellular memory to overcome drug resistance," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    2. Ruitong Li & Olaf Klingbeil & Davide Monducci & Michael J. Young & Diego J. Rodriguez & Zaid Bayyat & Joshua M. Dempster & Devishi Kesar & Xiaoping Yang & Mahdi Zamanighomi & Christopher R. Vakoc & Ta, 2022. "Comparative optimization of combinatorial CRISPR screens," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    3. Claudia Capparelli & Timothy J. Purwin & McKenna Glasheen & Signe Caksa & Manoela Tiago & Nicole Wilski & Danielle Pomante & Sheera Rosenbaum & Mai Q. Nguyen & Weijia Cai & Janusz Franco-Barraza & Ric, 2022. "Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    4. Benjamin Wölfl & Hedy te Rietmole & Monica Salvioli & Artem Kaznatcheev & Frank Thuijsman & Joel S. Brown & Boudewijn Burgering & Kateřina Staňková, 2022. "The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer," Dynamic Games and Applications, Springer, vol. 12(2), pages 313-342, June.
    5. Maria Gonzalez-Cao & Clara Mayo de las Casas & Juana Oramas & Miguel A. Berciano-Guerrero & Luis Cruz & Pablo Cerezuela & Ana Arance & Eva Muñoz-Couselo & Enrique Espinosa & Teresa Puertolas & Roberto, 2021. "Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial," Nature Communications, Nature, vol. 12(1), pages 1-6, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:494:y:2013:i:7436:d:10.1038_nature11814. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.